After nine years of developing and commercialising its technology in Europe, this medical devices business secured regulatory approval to sell to hospitals in America in 2016. It has created a minimally invasive and radiation-free way for surgeons to locate breast cancer tumours and lymph nodes and remove them accurately. Led by chief executive Eric Mayes, 49, it has raised close to £17m, most recently securing an £8m investment from Draper Esprit in July 2018. With sales of £6.3m last year, it plans to expand by using its technology in the treatment of other cancers, such as melanoma and prostate cancer, and to increase its presence in NHS hospitals this year.

This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.

Company details
Year2019
Rank63
CompanyEndomag
ActivityMedical device developer
LocationCambridge
Average 3 year sales growth72.36%
Latest sales £000s*6,284
Staff20
Founded2007
Websitewww.endomag.com

If applicable:

* supplied by company † annualised figure